"A research letter recently published in JAMA Oncology has provided some promising insights into the potential of Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in lowering the risk of colorectal cancer (CRC) among patients with type 2 diabetes. The study involved a national retrospective analysis of more than 1.2 million patients with type 2 diabetes, treated between 2005 and 2019. The findings were remarkable, showing that GLP-1 RAs reduced the risk for colorectal cancer by 44% compared with insulin and by 25% compared with metformin. This risk reduction was observed across the board, in overweight, obese, and nonobese patients alike."
Not about PCa but interesting: GLP-1 ... - Fight Prostate Ca...
Not about PCa but interesting: GLP-1 Receptor Agonists help with colorectal cancer
Written by
Maxone73
To view profiles and participate in discussions please or .
Read more about...
Not what you're looking for?
You may also like...
A 5 Year Study helping men make informed decisions about prostate cancer treatments completed...
completed study....
https://jamanetwork.com/journals/jama/article-abstract/2758599
Sexual function...
Statin use and mortality risk in men on ADT.
of the type of ADT used.
... Notably, these associations were more pronounced among patients...
New strategies against bone metastases from prostate cancer - Science Daily
From the paper:
There are two types of bone disease from metastases: lytic metastases,...
Efficacy and safety of BAT in CRPC following Abi or Enza resistance: A systematic review
castration-resistant prostate cancer (CRPC) that can restore some patients' sensitivity to drugs...
Vitamin D metabolism in cancer: potential feasibility of vitamin D metabolism blocking therapy
propose the potential feasibility of vitamin D metabolism-blocking therapy in various types of...
Will I be able to Radiate Prostate Bed Fossa, mass is abutting rectum and bladder?
